Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMineralys Therapeutics holds routine annual meeting, elects three directors
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
low
Stockholders elected three Class III directors to three-year terms expiring in 2029: Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas. All nominees received majority support.
Item 5.07 verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 72.6 million votes in favor, representing near-unanimous shareholder approval.
Item 5.07 verify on EDGAR →
Summary
Mineralys Therapeutics held its annual stockholder meeting on May 21, 2026, conducting routine corporate governance matters. The company's shareholders elected three directors to the board's Class III, each to serve three-year terms through 2029, and overwhelmingly ratified Ernst & Young as the company's auditor for the current fiscal year. For retail investors, this filing represents standard annual meeting business with no material changes to company operations, strategy, or financial outlook.
The strong shareholder support for both the director slate and auditor ratification suggests no governance controversies. Watch for the company's proxy statement and annual report filings, which will provide more detailed information about board composition, executive compensation, and strategic priorities for the coming year.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify